Company news
Biofrontera Inc. news in 2022
Biofrontera Inc.'s news releases, calls and decks from 2022, newest first.
Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
December 15, 2022
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
November 20, 2022
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
November 13, 2022
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
November 9, 2022
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG
November 7, 2022
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
October 30, 2022
Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
October 23, 2022
Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
October 17, 2022
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
October 13, 2022
Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022
October 4, 2022
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
September 12, 2022
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent
September 5, 2022
Biofrontera Inc.’s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology
August 17, 2022
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
August 11, 2022
Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
August 3, 2022
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
July 31, 2022
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
July 26, 2022
Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022
July 11, 2022
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
May 18, 2022
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
May 15, 2022
Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update
May 12, 2022
Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022
May 5, 2022
Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education
May 4, 2022
Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®
April 20, 2022
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
April 12, 2022
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
April 7, 2022
Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022
April 5, 2022
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022
March 31, 2022
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting
March 16, 2022
Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Protection of Ameluz®-PDT Through October 2040
March 13, 2022
Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors
March 6, 2022
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT
January 31, 2022
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
January 12, 2022
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
January 9, 2022